NCT05684692View on ClinicalTrials.gov

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

March 30, 2026

Study Completion Date

November 30, 2027

Conditions
SchwannomatosisSchwannomasPain, Chronic
Interventions
DRUG

Siltuximab

A chimeric immunoglobulin G mAb, via intravenous infusion.

DRUG

Erenumab-Aooe

Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.

DRUG

Siltuximab Matching Placebo

Dextrose 5% in water, via intravenous infusion.

DRUG

Erenumab-Aooe Matching Placebo

0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.

Trial Locations (1)

02215

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Recordati Rare Diseases

INDUSTRY

lead

Massachusetts General Hospital

OTHER